SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas stronger-than-expected Q3 results and upbeat outlook, including rapid growth expectations tied to AI data-center and hyperscaler demand, are driving attention. Traders largely welcomed the report, while others question margins, cash generation and whether the recent volatility has already priced in the growth.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

A steep correction in silver after its earlier surge is driving attention, with traders focused on persistent selling and whether support will hold. Many expect further declines, while others view the selloff as an oversold buying opportunity; claims of market manipulation remain speculation.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

XP is plunging amid a broad selloff in Brazilian assets after Lulas re-election, as traders focus on concerns about government spending, fiscal discipline, and currency weakness rather than a company-specific development. Many view the drop as an election-driven overreaction and are buying for a rebound, while others warn that political and macroeconomic risks could prolong pressure.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

SpaceXs filing urging the FCC to include NextNavs proposed 900 MHz license in satellite-to-mobile rules has renewed attention to the potential value of NNs spectrum. Traders see it as a meaningful endorsement and speculate about future commercial interest, while others stress that FCC approval remains pending and no SpaceX acquisition or partnership has been announced.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is under pressure after a sharp Q3 earnings miss and another cut to its 2026 outlook, which now calls for a loss. Traders are focused on weak appliance demand, shrinking margins and debt concerns, while some argue the selloff has made the stock a deep-value or bounce opportunity.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

FIGR is drawing attention amid a steep, persistent share-price decline, with bearish traders focused on insider and pre-IPO investor selling, a potential share overhang, and concerns about CEO credibility. Bulls counter that loan-marketplace growth and the tokenization opportunity support the business; bankruptcy claims remain speculation rather than an established development.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a technology-sector pullback and rebound, with traders debating whether the weakness is a healthy rotation or a deeper downturn tied to AI-spending concerns, higher rates and poor sector breadth. Some see a buying opportunity and signs of stabilization, while others cite weak momentum and bearish technical signals.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of topline results from the Phase 3 APPROACH trial of HLP003, its investigational adjunctive treatment for major depressive disorder. Traders are split between optimism that the readout could validate the program and concerns about uncertain efficacy and potential dilution.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

A rally in big tech and the Nasdaq is weighing on SQQQ, which moves inversely to the Nasdaq-100, while traders debate whether the rebound will continue or fade amid concerns about AI spending and tech valuations. Some are treating pullbacks in the fund as opportunities to position for renewed tech weakness, while others warn that the leveraged ETF can be costly to hold through market swings.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention as biotech shares attempt a rebound after a broad sector pullback, with traders tying sentiment to interest-rate expectations, M&A chatter and upcoming biotech catalysts. Some see the bounce and sector rotation as signs of recovery, while others caution that rate sensitivity and technical weakness could keep the group choppy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.read more...

Companies Pushing Experimental Treatments Toward Their Biggest Tests

These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session.
Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands at $1.9read more...

Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.read more...

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with...

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x...

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m...

Xencor Reaches Analyst Target Price

In recent trading, shares of Xencor, Inc (Symbol: XNCR) have crossed above the average analyst 12-month target price of $29.00, changing hands for $29.33/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuatio...

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Xencor Reports Second Quarter 2026 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026. We are excited to present XmAb819 results at ESMO this fall and...

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Pasadena, CA.

Xencor Inc

Extremely Bullish Sentiment

$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$29.18
Prev Close	$25.18
Open	$32.31
Dividend Yield	0.00%
50-Day Moving Average	$25.42
Beta	1.41
Avg. Volume	1.44M
PE Ratio	-13.45

52-Week High	$33.60
52-Week Low	$10.38
Market Capitalization	$2.17B
EPS (Annual)	-$1.24
Price to Book	4.31
Revenue Per Employee	$482,984.61

Feed

News

Sentiment

Earnings

Fundamentals

Info

XNCR Fundamentals